Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to…
Read the full articleYou might also wanna read
Celltrion Wins Korean Phase 1 IND Approval for CT-P68, Targeting 7.7 Trillion Won Market
Celltrion won Korean Phase 1 IND approval for CT-P68, a biosimilar of Johnson & Johnson's Tremfya, targeting a 7.73 trillion won autoimmune
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·1mo ago
Alchemab Therapeutics Announces Biggest Ever Life Sciences Investment from British Business Bank to Advance its AI-Enabled Clinical Pipeline of Next-Generation Human-Derived Antibodies
Alchemab Therapeutics, pioneering the next generation of antibody therapeutics for hard-to-treat diseases, led by Jane Osbourn, OBE, FMedSci
AstraZeneca compra a una farmacéutica de China los derechos de un medicamento pulmonar por 1.900 millones
Se trata de un inhibidor dual de PDE3/4 concebido para proporcionar efectos broncodilatadores y antiinflamatorios simultáneos.
The biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-ups
In this edition of the biotech bi-weekly: a new companion module makes direct RNA sequencing protocols more convenient, antibiotic design an
Alchemab Therapeutics extends Series A with £25m investment
Alchemab Therapeutics has extended its Series A financing with £25m from the British Business Bank, marking the Bank’s largest investment in
Comments
Sign in to join the conversation.
No comments yet. Be the first.